Royalty Pharma plc
RPRX evidence brief
What we can confirm
- BioSniper Score:
- 2.8 / 10
- Market Cap:
- $35.01B
- Next Catalyst:
- Patent_Expiry · Jul 28, 2036
What it means
What to watch
Prepared research question
What matters most for RPRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RPRX
Royalty Pharma plc (RPRX) is the largest buyer of biopharmaceutical royalties, funding innovation across the industry and holding a portfolio of royalties on more than 35 commercial products [sec_mda · as of 2026-05-06].
Key risk: Modest net income
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 28 clinical trials · 2 catalysts for Royalty Pharma plc.
Royalty Pharma plc (RPRX) is the largest buyer of biopharmaceutical royalties, funding innovation across the industry and holding a portfolio of royalties on more than 35 commercial products [sec_mda · as of 2026-05-06].
- Largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry [sec_mda · as of 2026-05-06].
- Portfolio includes royalties on more than 35 commercial products, including Vertex's Trikafta and Alyftrek, GSK's [sec_mda · as of 2026-05-06].
- Cash & equivalents $812.0M, total revenue $674.1M, net income $17.9M as of 2026-06-30 [sec].
- Announced transactions of $4.7 billion and royalty funding market reached record high of $10 billion in 2025 [news · published 2026-01-12].
- In March 2026, entered into an R&D co-funding agreement with Johnson & Johnson for $500 million over two years for JNJ‑4804 [sec_mda · as of 2026-08-05].
What works
- Strong execution and upside catalysts as it shifts to higher-IRR development assets [news · published 2026-08-26].
- Multiple potential value-creating milestones expected across development-stage portfolio in 2026, including pivotal data readouts for daraxonrasib, litifilimab and pelacarsen [news · published 2026-01-12].
- Royalty funding market reached record high of $10 billion in 2025, indicating robust market demand [news · published 2026-01-12].
What to weigh
- Net income of $17.9M as of 2026-06-30 is relatively modest compared to total revenue of $674.1M [sec].
- Dependence on regulatory and clinical milestones for future payments, such as $75 million payment upon European Medicines Agency approval for Avlayah by December 31, 2029 [sec_mda · as of 2026-08-05].
- Patent expirations for key products like VUTRISIRAN SODIUM (2036-07-28) and APALUTAMIDE (2040-01-30) could affect long-term royalty streams [catalyst].
From the filings
Quoted directly from source documents.
Royalty Pharma is the largest buyer of biopharmaceutical royalties.
“We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry.”
SEC MD&A · May 6, 2026
Portfolio includes royalties on more than 35 commercial products.
“We have assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry's leading therapies, which includes royalties on more than 35 commercial products, including Vertex's Trikafta and Alyftrek, GSK's”
SEC MD&A · May 6, 2026
Royalty funding market reached record high of $10 billion in 2025.
“Royalty funding market reached record high of $10 billion in 2025, powered by synthetic royalties”
News · January 12, 2026
Catalyst timeline
- 2036-07-28 · Patent_Expiry · VUTRISIRAN SODIUM — Patent expiry for NDA215515; may affect royalty stream from this product.
- 2040-01-30 · Patent_Expiry · APALUTAMIDE — Patent expiry for NDA210951; may affect royalty stream from this product.
Risks & what to watch (3)›
Key risks
- Modest net income — Net income of $17.9M on $674.1M revenue as of 2026-06-30 [sec].
- Milestone-dependent payments — Future payments like $75M for Avlayah depend on EMA approval by 2029-12-31 [sec_mda · as of 2026-08-05].
- Patent expirations — Patent expirations for VUTRISIRAN SODIUM (2036-07-28) and APALUTAMIDE (2040-01-30) may reduce royalty income [catalyst].
What to watch
- Pivotal data readouts for daraxonrasib, litifilimab and pelacarsen in 2026 [news · published 2026-01-12].
- FDA PDUFA date for neladalkib on November 27, 2026 [sec_mda · as of 2026-08-05].
- FDA PDUFA date for deucrictibant on April 23, 2027 [sec_mda · as of 2026-08-05].
- Progress of JNJ‑4804 development under $500 million co-funding with Johnson & Johnson [sec_mda · as of 2026-08-05].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Royalty Pharma plc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Royalty Pharma plc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
Net income $18M
No tracked pipeline phase
No tracked pipeline candidates
2 upcoming, next in ~3575d
0 buys · 17 sells (180d)
Catalysts
Regulatory
Financials
Short Interest
as of Apr 19, 2026- % of float
- 2.7%
- Days to cover
- 3.3
- Shares short
- 11,520,329
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RPRX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Royalty Pharma plc?
Royalty Pharma plc (RPRX) is the largest buyer of biopharmaceutical royalties, funding innovation across the industry and holding a portfolio of royalties on more than 35 commercial products [sec_mda · as of 2026-05-06].
What is Royalty Pharma plc's next catalyst?
Royalty Pharma plc's next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA215515" — expected July 28, 2036.
Who is the CEO of Royalty Pharma plc?
Mr. Pablo Legorreta is the chief executive officer of Royalty Pharma plc (RPRX).
Where is Royalty Pharma plc headquartered?
Royalty Pharma plc (RPRX) is headquartered in New York, NY, United States.
What therapeutic areas does Royalty Pharma plc focus on?
Royalty Pharma plc develops therapies across Oncology, Neurology, Immunology, Infectious Disease, Metabolic, Dermatology, Nephrology, Endocrinology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.